NASDAQ:AGEN

Agenus (AGEN) Stock Forecast, Price & News

$1.04

-0.09 (-7.92%)

(As of 01:45 PM ET)

Compare

Today's Range: $1.03
▼
$1.13
50-Day Range: $1.12
▼
$1.56
52-Week Range: $1.03
▼
$3.37

Volume: 1.64 million shs
Average Volume: 4.81 million shs
Market Capitalization: $394.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.10

Agenus MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 639.7% Upside
$8.10 Price Target
Short Interest: Bearish
7.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$280,747 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.77) to ($0.70) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

277th out of 969 stocks

Biological Products, Except Diagnostic Industry

41st out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Agenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.10, Agenus has a forecasted upside of 639.7% from its current price of $1.10.
Amount of Analyst Coverage
Agenus has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.71% of the outstanding shares of Agenus have been sold short.
Short Interest Ratio / Days to Cover
Agenus has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Agenus has recently decreased by 0.34%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Agenus does not currently pay a dividend.
Dividend Growth
Agenus does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agenus is -0.93.

2.7

News and Social Media Coverage

News Sentiment
Agenus has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Agenus this week, compared to 2 articles on an average week.
Search Interest
Only 25 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
12 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agenus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $280,747.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Agenus is held by insiders.
Percentage Held by Institutions
55.36% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agenus are expected to grow in the coming year, from ($0.77) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agenus is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agenus is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Agenus (NASDAQ:AGEN) Stock

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Price History

30 days | 90 days | 365 days | Advanced Chart

AGEN Stock News Headlines

September 20, 2023 | msn.com

New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer

September 1, 2023 | finance.yahoo.com

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2023 | Behind the Markets (Ad)

Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's

A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>

August 28, 2023 | finance.yahoo.com

Calculating The Intrinsic Value Of Agenus Inc. (NASDAQ:AGEN)

August 25, 2023 | seekingalpha.com

Agenus: Immuno-Oncology Advancements Amidst Fiscal Pressures

August 25, 2023 | markets.businessinsider.com

Agenus (AGEN) Receives a Buy from Robert W. Baird

August 24, 2023 | finance.yahoo.com

Herpes Simplex Virus Treatment Global Market Report 2023

August 24, 2023 | seekingalpha.com

Agenus to cut 25% staff as lead program takes priority

October 2, 2023 | Behind the Markets (Ad)

Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's

August 24, 2023 | finance.yahoo.com

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

August 23, 2023 | finance.yahoo.com

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

August 23, 2023 | markets.businessinsider.com

B.Riley Financial Sticks to Their Buy Rating for Agenus (AGEN)

August 23, 2023 | bizjournals.com

Lexington biotech lays off 91 as it narrows focus

August 23, 2023 | marketwatch.com

Agenus to Cut 25% of Staff, Focus on BOT/BAL Program >AGEN

August 12, 2023 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on Agenus (AGEN)

August 9, 2023 | finance.yahoo.com

SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant

August 8, 2023 | finance.yahoo.com

Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics

August 8, 2023 | msn.com

Agenus GAAP EPS of -$0.20 in-line, revenue of $25.3M beats by $1.17M

August 8, 2023 | markets.businessinsider.com

Agenus Inc. Q2 Earnings Summary

August 8, 2023 | finance.yahoo.com

Agenus Reports Second Quarter 2023 Results

August 7, 2023 | seekingalpha.com

Agenus Q2 2023 Earnings Preview

July 28, 2023 | finance.yahoo.com

Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

July 26, 2023 | finance.yahoo.com

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

July 5, 2023 | markets.businessinsider.com

Agenus (AGEN) Receives a Buy from Jefferies

July 3, 2023 | benzinga.com

EF Hutton Reiterates Buy on Agenus, Maintains $8.3 Price Target

July 3, 2023 | markets.businessinsider.com

B.Riley Financial Reaffirms Their Buy Rating on Agenus (AGEN)

June 30, 2023 | finance.yahoo.com

ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

See More Headlines

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings: 8/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:AGEN
CUSIP: 00847G70
CIK: 1098972
Web: agenusbio.com
Phone: (781) 674-4400
Fax: 781-674-4200
Employees: 533
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.10
High Stock Price Forecast: $8.30
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +616.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-220,070,000.00
Net Margins: -276.92%
Pretax Margin: -276.92%
Return on Equity: N/A
Return on Assets: -67.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.84
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: $99.36 million
Price / Sales: 4.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.18) per share
Price / Book: -6.28

Miscellaneous

Outstanding Shares: 379,572,000
Free Float: 361,353,000
Market Cap: $428.92 million
Optionable: Optionable
Beta: 1.42

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Garo H. Armen Ph.D. (Age 70)
Founder, Exec. Chairman & CEO
Comp: $1.31M

Ms. Christine M. Klaskin (Age 57)
VP of Fin., Principal Financial Officer & Principal Accounting Officer
Comp: $379.83k

Dr. Steven J. O'Day M.D. (Age 61)
Ph.D., Chief Medical Officer
Comp: $867.12k

Craig Winter
Chief Information Officer

Mr. Zack Armen
Head of Investor Relations

Ms. Robin E. Abrams J.D. (Age 59)
Chief Legal Officer

Ms. Stephanie Fagan
Chief Communications Officer

Ms. Tracy Mazza Clemente
Chief People Officer

Ms. Julie DeSander
Chief Bus. Officer

Mr. Dhan Chand
Scientific Director & Head of Drug Discovery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings or view top-rated stocks.
What is Agenus' stock price forecast for 2023?: 4 equities research analysts have issued 1 year target prices for Agenus' stock. Their AGEN share price forecasts range from $8.00 to $8.30. On average, they anticipate the company's share price to reach $8.10 in the next year. This suggests a possible upside of 616.8% from the stock's current price.
View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts.
How have AGEN shares performed in 2023?: Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN shares have decreased by 52.9% and is now trading at $1.13.
View the best growth stocks for 2023 here.
When is Agenus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our AGEN earnings forecast.
How were Agenus' earnings last quarter?: Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). The biotechnology company had revenue of $25.30 million for the quarter, compared to analysts' expectations of $23.98 million. During the same quarter in the prior year, the firm earned ($0.17) EPS.
What ETF holds Agenus' stock ?: WisdomTree BioRevolution Fund holds 20,765 shares of AGEN stock, representing 1.09% of its portfolio.

What is Garo H. Armen's approval rating as Agenus' CEO?: 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Agenus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).
What is Agenus' stock symbol?: Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How do I buy shares of Agenus?: Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Agenus' stock price today?: One share of AGEN stock can currently be purchased for approximately $1.13.
How much money does Agenus make?: Agenus (NASDAQ:AGEN) has a market capitalization of $428.92 million and generates $99.36 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.
How many employees does Agenus have?: The company employs 533 workers across the globe.
How can I contact Agenus?: Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial